Stability Assurance: RP-HPLC Method Development and Validation for Novel Dental Abscess Bulk Drugs Combinations

Dr. Aditi Kaushik

doi:10.35516/jjps.v18i4.2993

Authors

Dr. Aditi Kaushik Laureate Institute of Pharmacy

DOI:

https://doi.org/10.35516/jjps.v18i4.2993

Abstract

Background: This research focused on developing and validating a stability-indicating and RP-HPLC (Reverse Phase High-Performance Liquid Chromatography) method for the precise estimation of Metronidazole and Cefixime in bulk and formulation samples. The choice of Shim-pack C-18 column, with dimensions 250 X 4.6 mm then a particle size of 5 µm, was pivotal for achieving the desired chromatographic separation. The mobile phase used consisted of Methanol and Water in a ratio of 80:20 v/v.

Results: The chromatographic conditions yielded excellent results, with retention times of 3.127 minutes for Metronidazole and 2.096 minutes for Cefixime. The method demonstrated linearity across a concentration range of 5 to 30 µg/mL for both compounds. Furthermore, the Limit of Detection (LOD) and Limit of Quantification (LOQ) values were determined as 0.331/1.004 µg/mL for Metronidazole and 0.590/1.789 µg/mL for Cefixime, respectively.

Conclusion: In conclusion, the established RP-HPLC method underwent validation following ICH Q2 R1 guidelines to ascertain its accuracy, precision, and robustness. Its capacity to detect degradation products during stress testing, encompassing oxidation, photodegradation, acid, and base hydrolysis, validates it as a dependable stability-indicating technique. This method is suitable for the routine analysis of Metronidazole and Cefixime in pharmaceutical formulations, guaranteeing quality control and adherence to regulatory standards.

References

Msarton and Surgery for Dental Practitioners. Berlin, I.J.; Kiss, C. Protective and destructive immune reactions in apical periodontitis. Oral Microbial Immunol 2000, 15, 139–150.

Teoh, L.S.K.; Marino, R.; McCullough, M. Part 1. Current prescribing trends of antibiotics by dentists in Australia from 2012 to 2016. Aust. Dent. J. 2018, 63, 329–337.

Jain, V., Reghuvaran, K. M., Rastogi, S., &Asawa, K. (2015). Antibiotics in endodontics: A review. Journal of International Society of Preventive & Community Dentistry, 5(3), 173–177. https://doi.org/10.4103/2231-0762.159978

American Academy of Periodontology. "Periodontal (Gum) Abscess." Available online: https://www.perio.org/consumer/abscess.htm

National Center for Health Statistics, Centers for Disease Control and Prevention. "National Health and Nutrition Examination Survey (NHANES) Data." Available online: https://www.cdc.gov/nchs/nhanes/index.htm

Dye, B. A., Tan, S., Smith, V., Lewis, B. G., Barker, L. K., Thornton-Evans, G., Eke, P. I., Beltrán-Aguilar, E. D., Horowitz, A. M., & Li, C.-H. (2012). Trends in oral health status: United States, 1988-1994 and 1999-2004. Vital and Health Statistics. Series 11, Data from the National Health Survey, (248), 1–92.

Wang, D. H., Russell, J., &Spangehl, M. J. (2005). Hospital admissions for dental infections: a 10-year analysis. The Journal of Oral and Maxillofacial Surgery, 63(7), 1–5.

Graham, D. B., Webb, M. D., & Seal, J. R. (2000). Pediatric dental emergency room visits. The Journal of the Tennessee Dental Association, 80(1), 23–27.

Teoh, L.; Stewart, K.; Marino, R.J.; McCullough, M.J. Improvement of dental prescribing practices using education and a prescribing tool: A pilot intervention study. Br. J. Clin Pharmacol 2020, 87, 152–162.

Cope, A.L.; Francis, N.A.; Wood, F.; Chestnutt, I.G. Antibiotic prescribing in UK general dental practice: A cross-sectional study. Community Dent. Oral Epidemiol. 2016, 44, 145–153.

DrugBank. Metronidazole. Available at: https://go.drugbank.com/drugs/DB00916

National Center for Biotechnology Information. PubChem Compound Summary for CID 4173, Metronidazole. Available online: https://pubchem.ncbi.nlm.nih.gov/compound/Metronidazole (accessed on March 17, 2024).

FDA.Drugs@FDA: -Approved Drugs. Available online: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011269 (accessed on March 17, 2024).

Löfmark, S., &Edlund, C. (2010). Metronidazole is still the drug of choice for treatment of anaerobic infections. Clinical Infectious Diseases, 50(Supplement_1), S16-S23.

Haque, A., Zaman, S., Bakar, M. A., Aziz, M. A., & Rahman, A. (2017). Comparison between Metronidazole and Cefiximein the Management of Periapical Abscess. Bangladesh Journal of Medical Science, 16(2), 206-210.

Indian Pharmacopeia, Vol. Ⅱ, Government of India, The controller of Publication, Delhi, (2010), 1090-1094 & 1682-1686.

British Pharmacopeia, Vol. Ⅱ, Stationary Office, Medicines and Healthcare Products Regulatory, Agency, London, (2010), 2504-2505 & 2896-2898.

The United States Pharmacopeia, 32 Revision, NF 27, The United States Pharmacopeial Convention, Inc., Rockville, MD, (2009), 1939-1945 & 2971-2973.

Vol. 2. New Delhi: Controller of Publication, Govt. of India, Ministry of Health and Family Welfare; 2010. Indian Pharmacopoeia; p. 1012.

Vol. 1. London: HMSO Publication; 2009. British Pharmacopoeia; p. 397

United State of Pharmacopoeia 31 National Formulary 26. The standard of quality. United State Pharmacopoeial Convention Inc. 2009; 2:1671.

Lodise, T. P., & Lomaestro, B. M. (2005). Piperacillin-Tazobactam: A Unique Antibiotic Combination. Infectious Diseases Clinics of North America, 19(3), 625–643. https://doi.org/10.1016/j.idc.2005.05.005

Aronson, J. K. (Ed.). (2021). Meyler's Side Effects of Drugs (16th ed.). Elsevier. Chapter 34 - Cephalosporins.

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). "Validation of Analytical Procedures: Text and Methodology Q2 (R1)." ICH Harmonised Tripartite Guideline, 2005.

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2003). Stability testing of new drug substances and products Q1A(R2).